BrainsWay Reports Positive Data for Deep TMS in Smoking Cessation
Summary
BrainsWay reported positive clinical data for its Deep Transcranial Magnetic Stimulation system in smoking cessation. The study showed that participants receiving Deep TMS treatment achieved significantly higher quit rates compared to sham stimulation. BrainsWay's Deep TMS is already FDA-cleared for major depressive disorder, obsessive-compulsive disorder, and smoking addiction.
Why it matters
Smoking remains one of the leading preventable causes of death worldwide, and effective cessation aids are needed. Deep TMS offers a non-invasive, non-pharmacological approach to addressing nicotine addiction by targeting brain circuits involved in craving and reward. Positive data in smoking cessation could expand the addressable market for BrainsWay's Deep TMS platform and validate neurostimulation as a tool for addiction treatment.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial